These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12466783)

  • 21. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocardial perfusion and metabolism after transcoronary ablation of septum hypertrophy (TASH) in hypertrophic obstructive cardiomyopathy.
    Lerch H; Schäfers M; Gietzen F; Schäfers K; Kuwert T; Kuhn H; Schober O
    Nuklearmedizin; 1997 Sep; 36(6):218-22. PubMed ID: 9380540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging.
    Chen J; Nagaraj H; Bhambhani P; Kliner DE; Soman P; Garcia EV; Heo J; Iskandrian AE
    Int J Cardiovasc Imaging; 2012 Aug; 28(6):1375-84. PubMed ID: 21863321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.
    Gietzen FH; Leuner CJ; Obergassel L; Strunk-Mueller C; Kuhn H
    Heart; 2004 Jun; 90(6):638-44. PubMed ID: 15145866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.
    Dąbrowski M; Chojnowska L; Małek L; Spiewak M; Kuśmierczyk B; Koziarek J; Klisiewicz A; Miśko J; Witkowski A
    Kardiol Pol; 2012; 70(8):782-8. PubMed ID: 22933209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.
    Nakamura T; Iwanaga Y; Yasuda M; Kawamura T; Miyaji Y; Morooka H; Miyazaki S
    Int J Cardiovasc Imaging; 2016 Apr; 32(4):613-20. PubMed ID: 26589516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac electromechanical mapping in analyzing the mechanism of left ventricular remodeling immediately after percutaneous transluminal septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Chen SL; Huang J; Ye F; Shan SJ; Zhang JJ; Duan BX; Chen YD
    Chin Med J (Engl); 2005 Nov; 118(21):1779-85. PubMed ID: 16336814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy through non-left anterior descending septal perforators.
    Imori Y; Takano H; Kitamura M; Aoyama R; Sangen H; Kenta O; Matsuda J; Kubota Y; Tokita Y; Yamamoto T; Asai K; Takayama M; Shimizu W
    Heart Vessels; 2020 May; 35(5):647-654. PubMed ID: 31641886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.
    Sathyamurthy I; Nayak R; Oomman A; Subramanyan K; Kalarical MS; Mao R; Ramachandran P
    Indian Heart J; 2014; 66(1):57-63. PubMed ID: 24581097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy.
    Crossen K; Jones M; Erikson C
    Heart Rhythm; 2016 Sep; 13(9):1885-90. PubMed ID: 27132152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.
    Faber L; Prinz C; Welge D; Hering D; Butz T; Oldenburg O; Bogunovic N; Horstkotte D
    Int J Cardiovasc Imaging; 2011 Mar; 27(3):325-33. PubMed ID: 20694748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre.
    Wojtarowicz A; Kornacewicz-Jach Z
    Cardiol J; 2017; 24(2):125-130. PubMed ID: 27734458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy.
    Monakier D; Woo A; Puri T; Schwartz L; Ross J; Jamorski M; Yang H; Liu Z; Vannan M; Wigle ED; Rakowski H
    Am J Cardiol; 2004 Dec; 94(12):1515-22. PubMed ID: 15589007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy.
    Lakkis NM; Nagueh SF; Kleiman NS; Killip D; He ZX; Verani MS; Roberts R; Spencer WH
    Circulation; 1998 Oct; 98(17):1750-5. PubMed ID: 9788829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy.
    Rigopoulos AG; Seggewiss H
    Circ J; 2011; 75(1):28-37. PubMed ID: 21116069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.